According to the Wisdom Finance app, shares of Innovent Biologics (01801) rose more than 4%, and as of publication, rose 4.43% to HKD 37.70, with a turnover of HKD 74,983,600.
On July 9, Aurora Mobile-backed company, Suzhou Saint-Honoré Biotech, announced that the clinical trial application for SGB-3908, a small interfering RNA (siRNA) drug developed by Innovent Biologics and Saint-Honoré Biotech for the treatment of hypertension, has been granted the tacit approval (acceptance number: CXHL2400426) of the Clinical Trial Application Center (CDE) of the National Medical Products Administration (NMPA) for clinical trials of drugs. This is the third siRNA drug developed by Saint-Honoré Biotech for clinical trials in China after SGB-3403 and SGB-9768 injections.
In addition, CICC Research recently released a research report stating that Innovent Biologics has disclosed positive data on differentiated assets, including the results of the GLORY-1 Phase III study for Margenza peptide and preliminary data for potential first-in-class new molecular-type assets such as IBI343 and IBI363. In addition, the company's two assets, IBI112 and IBI311, have considerable market potential and have respectively approached or entered the stage of new drug listing review.